Enzalutamide + Ra223 shows rPFS benefits in asymptomatic or mildly symptomatic patients with bone-metastatic mCRPC: Results from the PEACE-3 trial

First-line lorlatinib shows 5-year benefits in Asian patients with ALK+ NSCLC: Post-hoc analysis from the CROWN trial

Endocrine therapy interruption in HR-positive breast cancer enables feasible and safe breastfeeding after conception